Bacterial infections are increasingly epitomizing major global health concerns, with rising death rates. Since the most complete assessment of the worldwide impact of antimicrobial resistance to date, with over 1.2 million people dead in 2019 as a direct result of antibiotic-resistant bacterial infections. The majority of antimicrobial drugs have been associated with a multitude of adverse effects including financial costs as well. Pyrrolidine derivatives have sparked the interest of researchers to create novel synthetic molecules with minimal side effect and drawbacks. To close the research gap, the current review discusses the synthetic compounds with active pyrrolidine scaffolds, critical findings and most crucially the structure–activity relationship that affects the activity of the ring over the last one and half decade.

Graphical abstract

Keywords:

Refrences

1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacol. Ther. 40(4), 277–283 (2015).
Google Scholar
2. World Health Organization. Antimicrobial resistance: global report on surveillance 22(1), 232 (2014).
Google Scholar
3. The PLOS Medicine Editors. Antimicrobial resistance: is the world unprepared. PLOS Med. 13(9), 1–3 (2016).
Google Scholar
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. J. Hosp. Med. 1, 5–20 (2013).
Google Scholar
5. O'Neill J. Antimicrobial resistance, tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist. 1, 1–20 (2014).
Google Scholar
6. Health matters: antimicrobial resistance. Public Health England, Health Matters Blogs (2015).
Google Scholar
7. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 325(5944), 1089–1093 (2009).
Medline CASGoogle Scholar
8. Lewis K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12(5), 371–387 (2013).
Medline CASGoogle Scholar
9. Norrby SR, Nord CE, Finch R. European Society of Clinical Microbiology and Infectious Diseases. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5(2), 115–119 (2005).
MedlineGoogle Scholar
10. David MZ, Siegel JD, Chambers HF, Daum RS. Determining whether methicillin-resistant Staphylococcus aureus is associated with health care. JAMA 299(5), 519–520 (2008).
Medline CASGoogle Scholar
11. Bhattacharya PK. Emergence of antibiotic-resistant bacterial strains, methicillin-resistant Staphylococcus aureus, extended spectrum beta lactamases, and multi-drug resistance is a problem similar to global warming. Rev. Soc. Bras. Med. 47(6), 815–816 (2014).
MedlineGoogle Scholar
12. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant Gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. 27(1), 3–15 (2008).
Medline CASGoogle Scholar
13. Oliva A, Costantini S, Angelis M et al. High potency of melaleuca alternifolia, essential oil against multi-drug resistant Gram-negative bacteria and methicillin-resistant Staphylococcus aureus. Molecules 23(10), 2584 (2018).
MedlineGoogle Scholar
14. Brickner SJ, Hutchinson DK, Barbachyn MR et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. 39(3), 673–679 (1996).
Medline CASGoogle Scholar
15. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18(3), 456–462 (1998).
Medline CASGoogle Scholar
16. Brickner S, Barbachyn M, Hutchinson D et al. Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against Gram-positive pathogens. J. Med. Chem. 51(7), 1981–1990 (2008).
Medline CASGoogle Scholar
17. Tsiodras S, Gold HS, Sakoulas GM et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207–208 (2001).
Medline CASGoogle Scholar
18. Gales AC, Sader HS, Andrade SS Lutz L, Machado A, Barth AL. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27(4), 300–302 (2006).
Medline CASGoogle Scholar
19. Raimondi MV, Presentato A, Li Petri G et al. New synthetic nitro-pyrrolomycins as promising antibacterial and anticancer agents. Antibiotics 9(6), 292 (2020).
CASGoogle Scholar
20. Raimondi MV, Listro R, Cusimano MG et al. Pyrrolomycins as antimicrobial agents. Microwave-assisted organic synthesis and insights into their antimicrobial mechanism of action. Bioorg. Med. Chem. 27(5), 721–728 (2019).
Medline CASGoogle Scholar
21. Spanò V, Rocca R, Barreca M et al. Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d] [1,2]oxazoles, a new class of antimitotic agents active against multiple malignant cell types. J. Med. Chem. 63(20), 12023–12042 (2020).
Medline CASGoogle Scholar
22. Cascioferro SM, Raimondi MV, Maggio B et al. A new class of phenylhydrazinylidene derivatives as inhibitors of Staphylococcus aureus biofolm formation. Med. Chem. Res. 25, 870–878 (2016).
CASGoogle Scholar
23. Whatmore JL, Swann E, Barraja P et al. Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents. Angiogenesis 5(1–2), 45–51 (2002).
Medline CASGoogle Scholar
24. Jampilek J. Heterocycles in medicinal chemistry. Molecules 24(21), 3839 (2019).
Medline CASGoogle Scholar
25. Gomtsyan A. Heterocycles in drugs and drug discovery. Chem. Heterocycl. Comp. 48, 7–10 (2012).
CASGoogle Scholar
26. Brown DG, Boström J. Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone. J. Med. Chem. 59, 4443–4458 (2016)
Medline CASGoogle Scholar
27. Steven AE, Paola B, Matthew AN et al. Controlling the rates of reductively-activated elimination from the (indol-3-yl) methyl position of indolequinones. J. Chem. Soc., Perkin Trans. 2. 5(8), 843–860 (2001).
Google Scholar
28. Clemons PA, Wilson JA, Dančík V et al. Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proc. Natl Acad. Sci. USA 108(17), 6817–6822 (2011).
Medline CASGoogle Scholar
29. Henary M, Kananda C, Rotolo L et al. Benefits and applications of microwave-assisted synthesis of nitrogen containing heterocycles in medicinal chemistry. RSC Adv. 10(24), 14170–14197 (2020).
Medline CASGoogle Scholar
30. Petri GL, V Spanò V, Spatola R et al. Bioactive pyrrole-based compounds with target selectivity. Eur. J. Med. Chem. 15(208), 112783 (2020).
Google Scholar
31. Cascioferro S, Raimondi MV, Cusimano MG et al. Pharmaceutical potential of synthetic and natural pyrrolomycins. Molecules 20(12), 21658–21671 (2015).
Medline CASGoogle Scholar
32. Raimondi MV, Schillaci D, Petruso S. Synthesis and anti-staphylococcal activity of new halogenated pyrroles related to pyrrolomycins. F. J. Heterocycl. Chem. 44(6), 1407–1411 (2007).
CASGoogle Scholar
33. Adrio J, Carretero JC. Stereochemical diversity in pyrrolidine synthesis by catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides. Chem. Commun. 55(80), 11979–11991 (2019).
Medline CASGoogle Scholar
34. Bhat AA, Tandon N, Tandon R. Pyrrolidine derivatives as anti-diabetic agents: current status and future prospects. Chemistry Select 7(6), 1–18 (2022).
Google Scholar
35. Takahashi H, Kuroyanagi J, Miyauchi R et al. Substituted pyrrolidine derivative. US201184554822 (2013).
Google Scholar
36. Tadiparthi R, Birajdhar S, Dond B et al. A process for preparation of (2s, 5r)-7-oxo-n-[(3s)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide. WO20151108861 (2015).
Google Scholar
37. Gaucher and Berangere, Piperidine, pyrrolidine and 2-oxo-1,3-oxazinane derivatives as inhibitors of bacterial efflux-pumps for the treatment of microbial infections. WO20170931571 (2017).
Google Scholar
38. Martin O, Gallienne-Boivineau E, Nicolas C. Compounds for their use as drugs for the treatment and/or the prevention of infection(s) caused by biofilm-forming bacteria. WO20160304341 (2016).
Google Scholar
39. Fu J, Patrick L, Madera AM et al. Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections. WO2015066413 (2015).
Google Scholar
40. Kemp MI, Martin LS, Michael DW et al. US106548532 (2017).
Google Scholar
41. Lunniss CJ, Palmer T, Pitt GRW. Antibacterial compounds. WO20131388601 (2016).
Google Scholar
42. Wiles JA, Phadke AS, Deshpande M et al. Disubstituted compounds for treatment of medical disorders. US110016002 (2021).
Google Scholar
43. Yang Z, Yang H, Ji J. β-lactam compounds, their preparation and use as antibacterial agents. WO20220274391 (2022).
Google Scholar
44. Brooks WH, Guida WC, Daniel KG. The significance of chirality in drug design and development. Curr. Top Med. Chem. 11(7), 760–770 (2011).
Medline CASGoogle Scholar
45. Kunitski M, Riehn C, Matylitsky V, Victor VM, Pilarisetti T, Bernhard B. Pseudorotation in pyrrolidine: rotational coherence spectroscopy and ab initio calculations of a large amplitude intramolecular motion. Phys. Chem. Chem. Phys. 12(1), 72–81 (2010).
Medline CASGoogle Scholar
46. Galloway WRJD, Isidro-Llobet A, Spring DR. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat. Commun. 1(80), 1–13 (2010).
MedlineGoogle Scholar
47. Kumar A, Gupta G, Srivastava S. Diversity oriented synthesis of pyrrolidines via natural carbohydrate solid acid catalyst. J. Comb. Chem. 12(4), 458–462 (2010).
Medline CASGoogle Scholar
48. Oskinen AM, Helaja J, Kumpulainen ET, Koivisto J, Mansikkamäki H, Rissanen K. Locked conformations for proline pyrrolidine ring: synthesis and conformational analysis of cis- and trans-4-tert-butylprolines. J. Org. Chem. 70(16), 6447–6453 (2005).
MedlineGoogle Scholar
49. Andrei S, Droc G, Stefan G. FDA approved antibacterial drugs. Discoveries (Craiova) 7(4), e102 (2019).
MedlineGoogle Scholar

Vol. 11, No. 6

Metrics

Downloaded 65 times

History

Received 9 May 2022

Accepted 1 September 2022

Published online 11 November 2022

Published in print November 2022

Information

Keywords

Acknowledgments

Lovely Professional University (LPU) provided the underlying infrastructure for AA Bhat, N Tandon and R Tandon to write this patent review and the authors are grateful to them.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download